{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:55:26Z","timestamp":1790837726742,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Inclusion body myositis (IBM) is the most common acquired myopathy in individuals over 50\u200ayears of age and remains refractory to conventional immunosuppressive therapies. This review summarizes recent advances in the understanding of IBM pathogenesis and highlights emerging therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      Recent studies have refined the understanding of the interplay between degenerative and immune-mediated mechanisms in IBM. Abnormal protein aggregation, impaired proteostasis, and alterations of the autophagic pathway contribute to muscle fiber degeneration. In parallel, increasing evidence supports a central role for highly differentiated cytotoxic CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells invading major histocompatibility complex class I-expressing muscle fibers. Recent immunophenotyping studies have identified expanded populations of terminally differentiated killer cell lectin-like receptor G1-expressing CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in blood and muscle, suggesting a potential role for these cells in sustaining chronic muscle injury. These findings have prompted the development of targeted immunotherapies aimed at selectively modulating pathogenic cytotoxic T-cell populations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>IBM appears to result from a complex interaction between degenerative and immune-mediated pathways. Improved characterization of the immune effector cells involved in muscle injury is opening new avenues for targeted therapies and may ultimately lead to treatments for this condition that currently lacks disease-modifying therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001198","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:00:10Z","timestamp":1788336010000},"page":"481-487","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Inclusion body myositis: new insights into pathogenesis and therapeutic perspectives"],"prefix":"10.1097","volume":"38","author":[{"given":"Fran\u00e7ois","family":"Fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1212\/WNL.28.1.8","article-title":"Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy","volume":"28","author":"Carpenter","year":"1978","journal-title":"Neurology"},{"issue":"(Pt 11)","key":"R2-20261001","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain J Neurol"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0046-8177(86)80180-0","article-title":"Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies","volume":"17","author":"Engel","year":"1986","journal-title":"Hum Pathol"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMra2415426","article-title":"Inflammatory myopathies","volume":"394","author":"Allenbach","year":"2026","journal-title":"N Engl J Med"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","article-title":"272nd ENMC international workshop: 10 Years of progress \u2013 revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands","volume":"37","author":"Lilleker","year":"2024","journal-title":"Neuromuscul Disord"},{"issue":"(Pt 3)","key":"R7-20261001","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain J Neurol"},{"key":"R8-20261001","first-page":"103","article-title":"Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis","volume":"30","author":"Dubourg","year":"2011","journal-title":"Acta Myol Myopathies Cardiomyopathies"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ana.410370107","article-title":"Ragged red fibers in normal aging and inflammatory myopathy","volume":"37","author":"Rifai","year":"1995","journal-title":"Ann Neurol"},{"key":"R11-20261001","first-page":"1897","article-title":"Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis","volume":"29","author":"Dion","year":"2002","journal-title":"J Rheumatol"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/ker001","article-title":"Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis","volume":"50","author":"Cox","year":"2011","journal-title":"Rheumatology"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/WNL.57.3.548","article-title":"A prospective natural history study of inclusion body myositis: Implications for clinical trials","volume":"57","author":"Rose","year":"2001","journal-title":"Neurology"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.3390\/ijms25052742","article-title":"Sporadic inclusion body myositis at the crossroads between muscle degeneration, inflammation, and aging","volume":"25","author":"Guglielmi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"1153789","DOI":"10.3389\/fimmu.2023.1153789","article-title":"Uncovering the significance of expanded CD8+ large granular lymphocytes in inclusion body myositis: Insights into T cell phenotype and functional alterations, and disease severity","volume":"14","author":"McLeish","year":"2023","journal-title":"Front Immunol"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/brain\/awz207","article-title":"Highly differentiated cytotoxic T cells in inclusion body myositis","volume":"142","author":"Greenberg","year":"2019","journal-title":"Brain J Neurol"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"e1374","DOI":"10.1212\/WNL.0000000000200013","article-title":"Immunophenotyping of inclusion body myositis blood T and NK cells","volume":"98","author":"Goyal","year":"2022","journal-title":"Neurology"},{"key":"R18-20261001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2026.03.001","article-title":"Myeloid dendritic cell subsets characterise muscle in patients with inclusion body myositis and correlate with the IFN-\u03b3 pathway and effector T cell markers","author":"Kirou","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R19-20261001","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2024.07.146","article-title":"546VP Deep immunoprofiling in inclusion body myositis and trajectory analysis","author":"Roy","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s43587-024-00645-9","article-title":"Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis","volume":"4","author":"Wischnewski","year":"2024","journal-title":"Nat Aging"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ajpath.2011.05.055","article-title":"Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-\u03b3 signaling cascade in attacked versus nonattacked myofibers","volume":"179","author":"Ivanidze","year":"2011","journal-title":"Am J Pathol"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/jnen\/nlae098","article-title":"Contribution of major histocompatibility complex class II immunostaining in distinguishing idiopathic inflammatory myopathy subgroups: a histopathological cohort study","volume":"83","author":"Lessard","year":"2024","journal-title":"J Neuropathol Exp Neurol"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1093\/brain\/awaf153","article-title":"Interferon-\u03b3 causes myogenic cell dysfunction and senescence in immune myopathies","volume":"148","author":"Hou","year":"2025","journal-title":"Brain"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1093\/brain\/awaf118","article-title":"Mitochondrial damage is associated with an early immune response in inclusion body myositis","volume":"148","author":"Kleefeld","year":"2025","journal-title":"Brain"},{"key":"R25-20261001","doi-asserted-by":"crossref","first-page":"eabi9196","DOI":"10.1126\/scitranslmed.abi9196","article-title":"Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis","volume":"14","author":"Britson","year":"2022","journal-title":"Sci Transl Med"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40478-025-01933-0","article-title":"Human induced pluripotent stem cell-derived myotubes to model inclusion body myositis","volume":"13","author":"Cant\u00f3-Santos","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"R27-20261001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ana.27167","article-title":"Loss of TDP-43 splicing repression occurs in myonuclei of inclusion body myositis patients","volume":"97","author":"Ikenaga","year":"2025","journal-title":"Ann Neurol"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/jnnp.2007.131334","article-title":"TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia","volume":"79","author":"Weihl","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R29-20261001","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp5730","article-title":"Seeding-competent TDP-43 persists in human patient and mouse muscle","volume":"16","author":"Lynch","year":"2024","journal-title":"Sci Transl Med"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R32-20261001","first-page":"316","article-title":"Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale","volume":"43","author":"Badrising","year":"2025","journal-title":"Clin Exp Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:01:48Z","timestamp":1790834508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001198","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}